Compare Essex Property Trust, Inc. (ESS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Merck & Co., Inc. — how do they compare? Essex Property Trust, Inc. trades at $297.52 (market cap $18.82B), while Merck & Co., Inc. trades at $127.13 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 16.2× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.54%). Which is the better fit depends on your goals.
| ESS | MRK | |
|---|---|---|
Market Cap | $18.82B | $305.29B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $129.52 |
52-Week Low | $239.61 | $77.60 |
Enterprise Value | $25.54B | $348.71B |
Dividend Yield | 3.54% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $297.29, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected soon. Fundamentals show robust profitability with a 30.03% net income margin and $669.67M net income for 2025, though valuation ratios like a P/E of 32.93 appear elevated. Recent news highlights sustainability initiatives and inclusion in the Russell Microcap Index.
The outlook for ESS is cautiously optimistic, supported by high West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts are mixed with a $294.25 consensus price target, slightly below the current price, suggesting limited near-term upside amid solid operational performance.
MRK's stock trades at $128.08, up 6.02% over the past day, reflecting strong momentum. The technical outlook is bullish based on moving averages, with key support at $121 and resistance at $126. Fundamentally, the company reported $65.01B in 2025 revenue with a net income margin of 13.59%, and recent earnings beats in Q3 2025 and Q4 2025 highlight operational strength. The pending acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, signaling strategic growth initiatives.
The investment outlook for MRK is positive, supported by analyst consensus with a $137.30 price target and 67.57% buy ratings. Key opportunities include robust profitability and pipeline expansion via M&A, while risks involve rising debt levels and competitive pressures in the pharmaceutical sector. Earnings growth and successful integration of acquisitions are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
